We are live on ! Find out more
RP

Regeneron Pharmaceuticals Portfolio holdings

AUM $177M
1-Year Est. Return 9.82%
This Fund
S&P 500
This Quarter Est. Return
+20.99%
1 Year Est. Return
+9.82%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.49B
AUM Growth
+$251M
Cap. Flow
-$6.3M
Cap. Flow %
-0.42%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
–
Reduced
–
Closed
2
Avg Time Held
2 quarters
Top 10 Avg Time Held
2 quarters
Top 20 Avg Time Held
2 quarters

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
TSVT icon
2seventy bio
TSVT
+$6.2M
2
BLUE icon
bluebird bio
BLUE
+$102K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ALNY icon
1
Alnylam Pharmaceuticals
ALNY
$30.2B
$1.45B 97.6%
4,444,445
– –
2024 Q4
2 quarters
NTLA icon
2
Intellia Therapeutics
NTLA
$1.69B
$34.7M 2.34%
3,702,995
– –
2024 Q4
2 quarters
ACET icon
3
Adicet Bio
ACET
$49.5M
$591K 0.04%
60,511
– –
2024 Q4
2 quarters
ADVM icon
4
DELISTED
Adverum Biotechnologies
ADVM
$389K 0.03%
180,909
– –
2024 Q4
2 quarters
BLUE icon
5
DELISTED
bluebird bio
BLUE
– –
-21,000
Closed -$102K –
TSVT icon
6
DELISTED
2seventy bio
TSVT
– –
-1,254,827
Closed -$6.2M –

Similar funds

SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
MSA
Marathon Strategic Advisors Pittsburgh, Pennsylvania $177M AUM 66.85% 1-Year Est. Return
HF
Holcombe Financial Atlanta, Georgia $177M AUM 13.35% 1-Year Est. Return
CWP
Clark Wealth Partners O'fallon, Illinois $177M AUM 22.36% 1-Year Est. Return
BFAG
Blackston Financial Advisory Group The Villages, Florida $177M AUM 21.44% 1-Year Est. Return
WFG
Wormser Freres Gestion Paris, France $177M AUM 13.84% 1-Year Est. Return
AAS
AdviceOne Advisory Services Glastonbury, Connecticut $177M AUM 26.65% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

Regeneron Pharmaceuticals's Q2 2025 Portfolio in Review

As of Q2 2025, Regeneron Pharmaceuticals held 6 positions worth $1.49B, up 20% from $1.23B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Regeneron Pharmaceuticals's Q2 2025 filing shows 2 closed positions. The largest sale was 2seventy bio, an estimated $6.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Regeneron Pharmaceuticals fully exited 2seventy bio in Q2 2025, selling an estimated $6.2M.
  • Regeneron Pharmaceuticals's ten largest holdings make up 100% of its $1.49B portfolio in Q2 2025.
  • Regeneron Pharmaceuticals opened 0 new positions and closed 2 in Q2 2025.
  • Regeneron Pharmaceuticals's portfolio value rose 20% quarter-over-quarter to $1.49B.

Based on Regeneron Pharmaceuticals's 13F filing for Q2 2025, filed 1 Aug 2025.